Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Rates
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
    • Corporate & Special Sales
  • About
    • About Us
    • Editorial Board
    • Editorial Contact
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow SNMMI on Twitter
  • Visit SNMMI on Facebook
OtherMI Focus (Invitation Only)

Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy

Yubin Miao and Thomas P. Quinn
Journal of Nuclear Medicine December 2020, jnumed.120.243840; DOI: https://doi.org/10.2967/jnumed.120.243840
Yubin Miao
1 University of Colorado Denver, United States;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas P. Quinn
2 University of Missouri-Columbia, United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Melanocortin-1 receptor (MC1R) and very late antigen-4 (VLA-4, integrin α4β1) are two attractive molecular targets for developing peptide radiopharmaceuticals for melanoma imaging and therapy. MC1R- and VLA-4-targeting peptides and peptide-conjugated Cornell prime dots (C' dots) can serve as delivery vehicles to target both diagnostic and therapeutic radionuclides to melanoma cells for imaging and therapy. This review highlights the advances of MC1R- and VLA-4-targeted radiolabeled peptides and peptide-conjugated C' dots for melanoma imaging and therapy. The promising preclinical and clinical results of these new peptide radiopharmaceuticals present an optimistic outlook for clinical translation into receptor-targeting melanoma imaging and radionuclide therapy in the future.

  • Molecular Imaging
  • Oncology: Melanoma
  • Radionuclide Therapy
  • Cornell prime dots
  • Melanocortin-1 receptor
  • melanoma imaging and therapy
  • peptide radiopharmaceuticals
  • very late antigen-4
  • Copyright © 2020 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

SNMMI members

SNMMI Member Login

Login to the site using your SNMMI member credentials

Individuals

Non-Member Login

Login as an individual user

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (2)
Journal of Nuclear Medicine
Vol. 62, Issue 2
February 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy
Yubin Miao, Thomas P. Quinn
Journal of Nuclear Medicine Dec 2020, jnumed.120.243840; DOI: 10.2967/jnumed.120.243840

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Advances in Receptor-Targeted Radiolabeled Peptides for Melanoma Imaging and Therapy
Yubin Miao, Thomas P. Quinn
Journal of Nuclear Medicine Dec 2020, jnumed.120.243840; DOI: 10.2967/jnumed.120.243840
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

MI Focus (Invitation Only)

  • What is T+? A Gordian Knot of Tracers, Thresholds & Topographies
  • Advances in Reactive Oxygen Species (ROS) Imaging
Show more MI Focus (Invitation Only)

Basic (Molecular Imaging: Peptides)

  • Optoacoustic imaging of Glucagon-like Peptide 1 Receptor with a near-infrared exendin-4 analog
Show more Basic (Molecular Imaging: Peptides)

Similar Articles

Keywords

  • Molecular imaging
  • Oncology: Melanoma
  • Radionuclide Therapy
  • Cornell prime dots
  • Melanocortin-1 receptor
  • melanoma imaging and therapy
  • peptide radiopharmaceuticals
  • very late antigen-4
SNMMI

© 2021 Journal of Nuclear Medicine

Powered by HighWire